Alzheimer’s disease is the leading cause of dementia in old age, affecting a large number of individuals in Israel and projected to triple by 2050. Traditional diagnosis methods involve a review of medical history and cognitive assessments, but new biological markers can now accurately diagnose Alzheimer’s at an early stage.
Prof. David Tana, a neurology expert, highlights the importance of early detection in guiding drug treatment and lifestyle changes to delay disease progression. The new test works by identifying protein deposits called amyloid in the blood, which accumulate in the brain and damage nerve cell communication, leading to Alzheimer’s disease.
The amyloid test is available for individuals over 18 who have been referred by a doctor for cognitive testing. The cost of the test is NIS 3,450, and it can be combined with additional tests for specific drug treatment or genetic prediction of the disease. Most private health insurances in Israel now cover the test, and it is expected to be subsidized by health funds soon.
In addition to the information on the Alzheimer’s test, there are various resources and links provided on the website, ranging from wedding planning to event workshops to cooking recipes. Users can explore topics from writing services to web hosting to sports forums, offering a diverse range of content for different interests and needs.